A.I. Burnasyan FMBC clinical bulletin. 2026 № 4
Rare Malignant Breast Tumors. Features of Diagnosis and Treatment
D.N. Astakhov, A.A. Zavialov, N.G. Stepanyants, A.V. Aksenenko
A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: Dmitrii N. Astakhov, : e-mail: astahovy@gmail.com
Abstract
Breast cancer manifests itself in various pathomorphological forms, from the most common invasive ductal and lobular carcinomas to rare subtypes of breast cancer, exceptional features of the manifestation of the pathological process and approaching them.
Each of the rare subtypes of breast cancer has exceptional biological features, characteristic atypical course of the disease, and for most of them there are no clear manifestations. Currently, there are no large studies on rare subtypes of malignant tumors of the breast, a recommendation for patients with this pathology has not been developed, and the prognosis has not been determined. In this review, rare malignant neoplasms of the breast are conditionally divided into tumors with a favorable prognosis (mucinous carcinoma, tubular carcinoma, cribiform carcinoma, invasive papillary carcinoma, medullary carcinoma) and with an unfavorable prognosis (pleomorphic lobular carcinoma, inflammatory carcinoma, metaplastic carcinoma, neuroendocrine carcinoma, micropapillary carcinoma), for each of the subtypes, the features of the clinical course of the disease, approaches to treatment are described.
Keywords: breast cancer, rare subtypes of breast cancer
For citation: Astakhov DN, Zavialov AA, Stepanyants NG, Aksenenko AV. Rare Malignant Breast Tumors. Features Of Diagnosis And Treatment. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2026.4:93-98. (In Russian) DOI: 10.33266/2782-6430-2026-4-93-98
REFERENCES
- Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23(29):7350–60.
- Астахов Д.Н., Степанянц Н.Г., Завьялов А.А., Баксиян Г.А., Аксененко А.В., Шейнин И.А., Жедринская Е.В. Силиконовая лимфаденопатия, ассоциированная с разрывом имплантатов молочных желез. Пластическая хирургия и эстетическая медицина. 2022;(3):93 98. Astakhov DN, Stepanyants NG, Zavyalov AA, Baksiyan GA, Aksenenko AV, Sheinin IA, Zhedrinskaya EV. Silicone lymphadenopathy associated with breast implant rupture. Plastic Surgery and Aesthetic Medicine. 2022;(3):93 98. (In Russ., In Engl.) https://doi.org/10.17116/plast.hirurgia202203193
- Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.
- WHO Classification of Tumours Editorial Board. Breast Tumours: World Health Organization classification of tumours. 5th ed. Lyon, France: IARC Press; 2019.
- Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat. 2008;111(3):541–7.
- Bae SY, Choi MY, Cho DH, Lee JE, Nam SJ, Yang JH. Mucinous carcinoma of the breast in comparison with invasive ductal carcinoma: clinicopathologic characteristics and prognosis. J Breast Cancer. 2011;14(4):308–13.
- Kim HS, Lee JU, Yoo TK, Chae BJ, Son D, Kim YJ, et al. Omission of Chemotherapy for the Treatment of Mucinous Breast Cancer: A Nationwide Study from the Korean Breast Cancer Society. J Breast Cancer. 2019
- Limaiem F, Mlika M. Tubular Breast Carcinoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. PMID: 31194380.
- Rakha EA, Lee AH, Evans AJ, Menon S, Assad NY, Hodi Z, et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol. 2010;28(1):99–104.
- Sun JY, Zhou J, Zhang WW, Li FY, He ZY, Wu SG. Tubular carcinomas of the breast: an epidemiologic study. Future Oncol. 2018;14(29): 3037–47.
- Limaiem F, Mlika M. Tubular Breast Carcinoma. StatPearls. Treasure Island (FL)2020.
- Page DL, Dixon JM, Anderson TJ, Lee D, Stewart HJ. Invasive cribriform carcinoma of the breast. Histopathology. 1983;7(4):525–36.
- Liu XY, Jiang YZ, Liu YR, Zuo WJ, Shao ZM. Clinicopathological Characteristics and Survival Outcomes of Invasive Cribriform Carcinoma of Breast: A SEER Population-Based Study. Medicine (Baltimore). 2015;94(31):e1309.
- Fakhreddine MH, Haque W, Ahmed A, Schwartz MR, Farach AM, Paulino AC, et al. Prognostic Factors, Treatment, and Outcomes in Early Stage, Invasive Papillary Breast Cancer: A SEER Investigation of Less Aggressive Treatment in a Favorable Histology. Am J Clin Oncol. 2018;41(6):532–7.
- Mills MN, Yang GQ, Oliver DE, Liveringhouse CL, Ahmed KA, Orman AG, et al. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis. Eur J Cancer. 2018;98:48–58.
- Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet. 1997;349(9064):1505–10.
- Eichhorn JH. Medullary carcinoma, provocative now as then. Semin Diagn Pathol. 2004;21(1):65–73.
- Vu-Nishino H, Tavassoli FA, Ahrens WA, Haffty BG. Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT). Int J Radiat Oncol Biol Phys. 2005;62(4):1040–7.
- Haque W, Arms A, Verma V, Hatch S, Brian Butler E, Teh BS. Outcomes of pleomorphic lobular carcinoma versus invasive lobular carcinoma. Breast. 2019;43:67–73.
- Buchanan CL, Flynn LW, Murray MP, Darvishian F, Cranor ML, Fey JV, et al. Is pleomorphic lobular carcinoma really a distinct clinical entity? J Surg Oncol. 2008;98(5):314–7.
- Lim B, Woodward WA, Wang X, Reuben JM, Ueno NT. Inflammatory breast cancer biology: the tumour microenvironment is key. Nat Rev Cancer. 2018;18(8):485–99.
- Wu SG, Zhang WW, Wang J, Dong Y, Sun JY, Chen YX, et al. Inflammatory breast cancer outcomes by breast cancer subtype: a population-based study. Future Oncol. 2019;15(5):507–16.
- Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992. Cancer. 1998;82(12):2366–72.
- Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22(3):515–23.
- Cooper CL, Karim RZ, Selinger C, Carmalt H, Lee CS, O’Toole SA. Molecular alterations in metaplastic breast carcinoma. J Clin Pathol. 2013;66(6):522–8.
- Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2007;14(1):166–73.
- Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat. 2009;117(2):273–80.
- Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999;10(4):413–9.
- Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–81.
- Lester TR, Hunt KK, Nayeemuddin KM, Bassett RL, Jr., Gonzalez-Angulo AM, Feig BW, et al. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat. 2012;131(1):41–8.
- Wang J, Wei B, Albarracin CT, Hu J, Abraham SC, Wu Y. Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer. 2014;14:147.
- Zhu Y, Li Q, Gao J, He Z, Sun R, Shen G, et al. Clinical features and treatment response of solid neuroendocrine breast carcinoma to adjuvant chemotherapy and endocrine therapy. Breast J. 2013;19(4):382–7.
- Lavigne M, Menet E, Tille JC, Lae M, Fuhrmann L, Bonneau C, et al. Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. Mod Pathol. 2018;31(1):68–82.
- Yildirim Y, Elagoz S, Koyuncu A, Aydin C, Karadayi K. Management of neuroendocrine carcinomas of the breast: A rare entity. Oncol Lett. 2011;2(5):887–90.
- Yun SU, Choi BB, Shu KS, Kim SM, Seo YD, Lee JS, et al. Imaging findings of invasive micropapillary carcinoma of the breast. J Breast Cancer. 2012;15(1):57–64.
- Guo X, Chen L, Lang R, Fan Y, Zhang X, Fu L. Invasive micropapillary carcinoma of the breast: association of pathologic features with lymph node metastasis. Am J Clin Pathol. 2006;126(5):740–6.
- Chen AC, Paulino AC, Schwartz MR, Rodriguez AA, Bass BL, Chang JC, et al. Prognostic markers for invasive micropapillary carcinoma of the breast: a population-based analysis. Clin Breast Cancer. 2013;13(2):133–9.
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 06.04.2026. Accepted for publication: 20.04.2026